# US 2003/0215813 A1 · Human ion channels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215813 A1
- Document ID: US20030215813A1
- Status: Published application
- Kind: A1
- Application number: 10/149,930
- Filed: 2002-10-21
- Published: 2003-11-20
- Earliest claimed: 2002-10-21
- Inventors: Steven L. Roberds; Alla M. Karnovsky; Cara L. Ruble; Christopher W. Benjamin
- Web page: https://patentgrep.com/patent/US20030215813A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides novel ion channel polypeptides and polynucleotides which identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel agonists/antagonists, useful for the treatment of human diseases and conditions.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50, and fragments thereof; said nucleic acid molecule encoding at least a portion of ion-x.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1 comprising a sequence that encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50, and fragments thereof.

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1 comprising a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49 and SEQ ID NO:51, and fragments thereof.

### Claim 4 (depends on 1)

The isolated nucleic acid molecule of claim 1 comprising a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49 and SEQ ID NO:51, and fragments thereof.

### Claim 5 (depends on 4)

The isolated nucleic acid molecule of claim 4 comprising a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 6 (depends on 4)

The isolated nucleic acid molecule of claim 4 wherein said nucleotide sequence is selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 7 (depends on 1)

The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is DNA.

### Claim 8 (depends on 1)

The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is RNA.

### Claim 9 (depends on 1, 2, 3, 4, 5)

An expression vector comprising a nucleic acid molecule of any one of claims 1 to 5.

### Claim 10 (depends on 9)

The expression vector of claim 9 wherein said nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 11 (depends on 9)

The expression vector of claim 9 wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 12 (depends on 9)

The expression vector of claim 9 wherein said vector is a plasmid.

### Claim 13 (depends on 9)

The expression vector of claim 9 wherein said vector is a viral particle.

### Claim 14 (depends on 13)

The expression vector of claim 13 wherein said vector is selected from the group consisting of adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses.

### Claim 15 (depends on 9)

The expression vector of claim 9 wherein said nucleic acid molecule is operably connected to a promoter selected from the group consisting of simian virus 40, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metalothionein.

### Claim 16 (depends on 10)

A host cell transformed with an expression vector of claim 10.

### Claim 17 (depends on 16)

The transformed host cell of claim 16 wherein said cell is a bacterial cell.

### Claim 18 (depends on 17)

The transformed host cell of claim 17 wherein said bacterial cell is E. coli.

### Claim 19 (depends on 16)

The transformed host cell of claim 16 wherein said cell is yeast.

### Claim 20 (depends on 19)

The transformed host cell of claim 19 wherein said yeast is S. cerevisiae.

### Claim 21 (depends on 16)

The transformed host cell of claim 16 wherein said cell is an insect cell.

### Claim 22 (depends on 21)

The transformed host cell of claim 21 wherein said insect cell is S. frugiperda.

### Claim 23 (depends on 16)

The transformed host cell of claim 16 wherein said cell is a mammalian cell.

### Claim 24 (depends on 23)

The transformed host cell of claim 23 wherein mammalian cell is selected from the group consisting of chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human 293 cells, and murine 3T3 fibroblasts.

### Claim 25

An isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51, said portion comprising at least 10 nucleotides.

### Claim 26 (depends on 25)

The nucleic acid molecule of claim 25 wherein said molecule is an antisense oligonucleotide directed to a region of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 27 (depends on 26)

The nucleic acid molecule of claim 26 wherein said oligonucleotide is directed to a regulatory region of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 28 (depends on 25)

The nucleic acid molecule of claim 25 wherein said molecule is an antisense oligonucleotide directed to a region of nucleotide sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51.

### Claim 29 (depends on 1, 2, 3, 4, 5, 25)

A composition comprising a nucleic acid molecule of any one of claims 1 to 5 or 25 and an acceptable carrier or diluent.

### Claim 30 (depends on 9)

A composition comprising a recombinant expression vector of claim 9 and an acceptable carrier or diluent.

### Claim 31 (depends on 9)

A method of producing a polypeptide that comprises a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50, and homologs and fragments thereof, said method comprising the steps of:
a) introducing a recombinant expression vector of claim 9 into a compatible host cell;
b) growing said host cell under conditions for expression of said polypeptide; and
c) recovering said polypeptide.

### Claim 32 (depends on 31)

The method of claim 31 wherein said host cell is lysed and said polypeptide is recovered from the lysate of said host cell.

### Claim 33 (depends on 31)

The method of claim 31 wherein said polypeptide is recovered by purifying the culture medium without lysing said host cell.

### Claim 34 (depends on 1)

An isolated polypeptide encoded by a nucleic acid molecule of claim 1.

### Claim 35 (depends on 34)

The polypeptide of claim 34 wherein said polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50.

### Claim 36 (depends on 34)

The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group consisting of SEQ ID NO10 to SEQ ID NO:32, and SEQ ID NO:50.

### Claim 37 (depends on 34)

The polypeptide of claim 34 wherein said sequence homologous to a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50, comprises at least one conservative amino acid substitution compared to the sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50.

### Claim 38 (depends on 34)

The polypeptide of claim 34 wherein said polypeptide comprises a fragment of a polypeptide with a sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50.

### Claim 39 (depends on 34)

The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS:10-17, 22-28, 31, 32, and SEQ ID NO:50.

### Claim 40 (depends on 34)

A composition comprising a polypeptide of claim 34 and an acceptable carrier or diluent.

### Claim 41 (depends on 34)

An isolated antibody which binds to an epitope on a polypeptide of claim 34.

### Claim 42 (depends on 41)

The antibody of claim 41 wherein said antibody is a monoclonal antibody.

### Claim 43 (depends on 41)

A composition comprising an antibody of claim 41 and an acceptable carrier or diluent.

### Claim 44 (depends on 34)

A method of inducing an immune response in a mammal against a polypeptide of claim 34 comprising administering to said mammal an amount of said polypeptide sufficient to induce said immune response.

### Claim 45

A method for identifying a compound which binds ion-x comprising the steps of:
a) contacting ion-x with a compound; and
b) determining whether said compound binds ion-x.

### Claim 46 (depends on 45)

The method of claim 45 wherein the ion-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:32, and SEQ ID NO:50.

### Claim 47 (depends on 45)

The method of claim 45 wherein binding of said compound to ion-x is determined by a protein binding assay.

### Claim 48 (depends on 45)

The method of claim 45 wherein said protein binding assay is selected from the group consisting of a gel-shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, and ELISA.

### Claim 49 (depends on 45)

A compound identified by the method of claim 45.

### Claim 50

A method for identifying a compound which binds a nucleic acid molecule encoding ion-x comprising the steps of:
a) contacting said nucleic acid molecule encoding ion-x with a compound; and
b) determining whether said compound binds said nucleic acid molecule.

### Claim 51 (depends on 50)

The method of claim 50 wherein binding is determined by a gel-shift assay.

### Claim 52 (depends on 50)

A compound identified by the method of claim 50.

### Claim 53

A method for identifying a compound which modulates the activity of ion-x comprising the steps of:
a) contacting ion-x with a compound; and
b) determining whether ion-x activity has been modulated.

### Claim 54 (depends on 53)

The method of claim 53 wherein the ion-x comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:10 to SEQ ID NO:17, SEQ ID NO:22 to SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:50.

### Claim 55 (depends on 53)

The method of claim 53 wherein said activity is neuropeptide binding.

### Claim 56 (depends on 53)

The method of claim 53 wherein said activity is neuropeptide signaling.

### Claim 57 (depends on 53)

A compound identified by the method of claim 53.

### Claim 58

A method of identifying an animal homolog of ion-x comprising the steps:
a) comparing the nucleic acid sequences of the animal with a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51, and portions thereof, said portions being at least 10 nucleotides; and
b) identifying nucleic acid sequences of the animal that are homologous to said sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51, and portions thereof.

### Claim 59 (depends on 58)

The method of claim 58 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51 and portions thereof, said portions being at least 10 nucleotides, is performed by DNA hybridization.

### Claim 60 (depends on 58)

The method of claim 58 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51, and portions thereof, said portions being at least 10 nucleotides is performed by computer homology search.

### Claim 61

A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:
(a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one ion channel that is expressed in the brain, wherein the ion channel comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:17, SEQ ID NO:22 to SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:50, and allelic variants thereof, and wherein the nucleic acid corresponds to a gene encoding the ion channel; and
(b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the ion channel correlates with an increased risk of developing the disorder.

### Claim 62 (depends on 61)

A method according to claim 61, wherein the assaying step comprises at least one procedure selected from the group consisting of:
a) comparing nucleotide sequences from the human subject and reference sequences and determining a difference of either
at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an ion-1 allele and an ion-1 reference sequence, or
at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an ion-3 allele and an ion-3 reference sequence;
(b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences;
(c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and
(d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

### Claim 63 (depends on 62)

A method according to claim 62 wherein the assaying step comprises: performing a polymerase chain reaction assay to amplify nucleic acid comprising ion-1 or ion-3 coding sequence, and determining nucleotide sequence of the amplified nucleic acid.

### Claim 64

A method of screening for an ion-1 or ion-3 mental disorder genotype in a human patient, comprising the steps of:
(a) providing a biological sample comprising nucleic acid from said patient, said nucleic acid including sequences corresponding to allelles of ion-1 or ion-3; and
(b) detecting the presence of one or more mutations in the ion-1 allelle or the ion-3 allelle;
wherein the presence of a mutation in an ion-1 allelle or ion-3 allele is indicative of a mental disorder genotype.

### Claim 65 (depends on 64)

The method according to claim 64 wherein said biological sample is a cell sample.

### Claim 66 (depends on 64)

The method according to claim 64 wherein said detecting the presence of a mutation comprises sequencing at least a portion of said nucleic acid, said portion comprising at least one codon of said ion-1 or ion-3 alleles.

### Claim 67 (depends on 64)

The method according to claim 64 wherein said nucleic acid is DNA.

### Claim 68 (depends on 64)

The method according to claim 64 wherein said nucleic acid is RNA.

### Claim 69

A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:
(a) an oligonucleotide useful as a probe for identifying polymorphisms in a human ion-1 gene or a human ion-3 gene, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human ion-1 or ion-3 gene sequence or ion-1 or ion-3 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and
(b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with a mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

### Claim 70

A method of identifying an ion channel allelic variant that correlates with a mental disorder, comprising steps of:
(a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;
(b) detecting in the nucleic acid the presence of one or more mutations in an ion channel that is expressed in the brain, wherein the ion channel comprises an amino acid sequence selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:17, SEQ ID NO:22 to SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:50, and allelic variants thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding the ion channel;
wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

### Claim 71 (depends on 70)

A method according to claim 70, wherein the one or more ion channel is ion-1, ion-3, or an allelic variant thereof.

### Claim 72 (depends on 70)

A purified and isolated polynucleotide comprising a nucleotide sequence encoding an ion-1 or ion-3 allelic variant identified according to claim 70.

### Claim 73 (depends on 72)

A host cell transformed or transfected with a polynucleotide according to claim 72 or with a vector comprising the polynucleotide.

### Claim 74

A purified polynucleotide comprising a nucleotide sequence encoding ion-1 of a human with a mental disorder;
wherein said polynucleotide hybridizes to the complement of SEQ ID NO:49 under the following hybridization conditions:
(a) hybridization for 16 hours at 42° C. in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and
(b) washing 2 times for 30 minutes at 60° C. in a wash solution comprising 0.1×SSC and 1% SDS; and
wherein the polynucleotide that encodes ion-1 amino acid sequence of the human differs from SEQ ID NO:50 by at least one residue.

### Claim 75 (depends on 74)

A vector comprising a polynucleotide according to claim 74.

### Claim 76 (depends on 74)

A host cell that has been transformed or transfected with a polynucleotide according to claim 74 and that expresses the ion-1 protein encoded by the polynucleotide.

### Claim 77 (depends on 76)

A host cell according to claim 76 that has been co-transfected with a polynucleotide encoding the ion-1 amino acid sequence set forth in SEQ ID NO:50 and that expresses the ion-1 protein having the amino acid sequence set forth in SEQ ID NO:50.

### Claim 78 (depends on 76)

A method for identifying a modulator of biological activity of ion-1 or ion-3 comprising the steps of:
a) contacting a cell according to claim 76 in the presence and in the absence of a putative modulator compound;
b) measuring ion-1 or ion-3 biological activity in the cell;
wherein decreased or increased ion-1 or ion-3 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

### Claim 79

A method to identify compounds useful for the treatment of a mental disorder, said method comprising steps of:
(a) contacting a composition comprising ion-1 with a compound suspected of binding ion-1 or contacting a composition comprising ion-3 with a compound suspected of binding ion-3;
(b) detecting binding between ion-1 and the compound suspected of binding ion-1 or between ion-3 and the compound suspected of binding ion-3;
wherein compounds identified as binding ion-1 or ion-3 are candidate compounds useful for the treatment of a mental disorder.

### Claim 80

A method for identifying a compound useful as a modulator of binding between ion-1 and a binding partner of ion-1 or between ion-3 and a binding partner of ion-3 comprising the steps of:
(a) contacting the binding partner and a composition comprising ion-1 or ion-3 in the presence and in the absence of a putative modulator compound;
(b) detecting binding between the binding partner and ion-1 or ion-3;
wherein decreased or increased binding between the binding partner and ion-1 or ion-3 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a mental disorder.

### Claim 81 (depends on 79, 80)

A method according to claim 79 or 80 wherein the composition comprises a cell expressing ion-1 or ion-3 on its surface.

### Claim 82 (depends on 81)

A method according to claim 81 wherein the composition comprises a cell transformed or transfected with a polynucleotide that encodes ion-1 or ion-3.

### Claim 83

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to SEQ ID NO:50, and fragments thereof; said nucleic acid molecule encoding at least a portion of ion-1.

### Claim 84 (depends on 83)

An isolated polypeptide encoded by a nucleic acid molecule of claim 83.

### Claim 85

A chimeric receptor comprising at least a portion of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9, SEQ ID NO:49, and SEQ ID NO:51, said portion comprising at least 10 nucleotides.

### Claim 86 (depends on 85)

The chimeric receptor of claim 85 wherein the chimeric receptor comprises at least a portion of SEQ ID NO:49.
